£ 1492.5
Key Takeaways
Risk factor
Low price volatility
Profitability factor
Greatly undervalued vs peers
About
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza,...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, of fair value on E
Target Price
The average target price of GSK.L is 1647 and suggests 10% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
